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Abstract: Obesity is a global epidemic and coupled with the unprecedented growth of the world’s 
older adult population, a growing number of individuals are both old and obese. Whilst both 
ageing and obesity are associated with an increased prevalence of chronic health conditions and a 
substantial economic burden, evidence suggests that the coincident effects exacerbate negative health 
outcomes. A signifcant contributor to such detrimental effects may be the reduction in the contractile 
performance of skeletal muscle, given that poor muscle function is related to chronic disease, poor 
quality of life and all-cause mortality. Whilst the effects of ageing and obesity independently on 
skeletal muscle function have been investigated, the combined effects are yet to be thoroughly 
explored. Given the importance of skeletal muscle to whole-body health and physical function, the 
present study sought to provide a review of the literature to: (1) summarise the effect of obesity on 
the age-induced reduction in skeletal muscle contractile function; (2) understand whether obesity 
effects on skeletal muscle are similar in young and old muscle; (3) consider the consequences of these 
changes to whole-body functional performance; (4) outline important future work along with the 
potential for targeted intervention strategies to mitigate potential detrimental effects. 
Keywords: high-fat diet; sarcopenia; muscle ageing; isolated skeletal muscle 
1. Introduction 
Obesity is a global epidemic [1] associated with poor physical and mental health, 
reduced quality of life, and increased morbidity and mortality [2–5]. More specifcally, 
obesity has been linked to increased risk of cardiovascular disease, insulin resistance, non-
alcoholic fatty liver disease, subfertility and cancer [5]. Obesity is also recognised to have 
substantial economic repercussions as a result of reduced productivity, unemployment and 
direct health care costs [6]. In 2014, the global economic impact of obesity was estimated to 
be USD 2 trillion, or 2.8% of the global gross domestic product (GDP) [7]. 
The world is faced with unprecedented growth in the older adult population [8], which 
is accompanied by an increased prevalence of chronic diseases and hence a substantial 
economic cost for health care [9,10]. Data from the US indicate a growing trend in the 
prevalence of obesity in adults aged >60 years, with over 37% of this population being 
obese [11]. Recent data from the UK demonstrate that the proportion of adults that are 
obese increases with age, with ~30% of adults >65 years being classifed as obese [12]. 
Given the growth in the world’s old obese population, there has been a recent surge in 
literature examining the combined effects of increasing age and obesity on markers of 
health and physiological function. When compared to the independent effects of increasing 
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age and obesity, old obese adults have an increased risk of cardiovascular disease (CVD), 
metabolic disorders, and all-cause mortality [13–17]. One important target for investigation 
has been skeletal muscle. Skeletal muscle is the largest regulator of metabolism in the 
body, and effective contractile function is required for locomotor performance and physical 
activity [18]. More specifcally, muscle weakness is independently related to fall risk, 
chronic disease, poor quality of life and greater all-cause mortality [19–22]. Whilst the 
effects of age on contractile function are well established [23–26], there is growing evidence 
that obesity also has a negative effect on muscle function that may in turn act as a catalyst 
to a negative obesity cycle [27], thus exacerbating the detrimental effects of high adiposity 
on physiological function and health in old age. Despite these suggestions, evidence for 
the negative effects of obesity and ageing on the contractile function of skeletal muscle 
appear limited and controversial. 
2. Defning Skeletal Muscle Contractile Function 
Some of the ambiguity in understanding the direct effects of obesity on skeletal muscle 
contractile function are linked specifcally to the defnition of muscle function. As such, in 
the context of this review, it is important to defne this at the outset. Whilst previous work in 
this area has employed a variety of methodological procedures, skeletal muscle contractility 
has primarily been assessed in three ways. Most studies focus on the absolute maximal 
strength (force output) or power (force x velocity of movement) -producing capacity of 
a muscle or muscle group [28–30] and other studies have also examined the contractile 
function normalised to body mass (i.e., force to body mass) [31–34]. Such measures are 
important in understanding the biomechanical consequences of changes in muscle function 
and limits to functional performance. To a much lesser extent, previous work has examined 
the maximal force or power output normalised to muscle size (typically cross-sectional area 
or muscle mass) as an indicator of muscle quality [34–36]. These latter studies suggested 
an obesity-induced reduction in the intrinsic force-producing capacity of skeletal muscle, 
or muscle quality, and explains the lower force or power despite larger muscles in the 
obese [18,37]. In addition, larger muscles of poorer quality also result in greater body 
inertia and an increased cost of maintenance, repair and regeneration [27]. Each of these 
measures not only provides valuable insight into understanding of the direct impact on 
skeletal muscle function but also allows inferences with respect to functional consequences. 
As such, in this review, we will consider the effects of age, obesity and their potential 
additive effect on each of these aspects of skeletal muscle function. 
The combined effects of ageing and obesity on skeletal muscle are commonly re-
ferred to as sarcopenic obesity [13,14,38]. Sarcopenia, defned as an age-related reduction 
in muscle mass and an associated reduction in contractile function [25], is commonly 
referred to in the published literature exploring the effects of age on skeletal muscle 
function [24–26,39–42]. In the context of the current review, we choose not to refer to 
the term sarcopenic obesity. Skeletal muscle ageing can occur without substantial atro-
phy [43,44], and in many of the studies examining the effects of both ageing and obesity 
on contractile function, skeletal muscle mass is not measured [31,32] or is unchanged or 
increased [45,46]. 
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3. The Independent Effects of Increasing Age and Obesity on Skeletal Muscle 
Contractile Function 
Despite the complexities associated with understanding the muscle-specifc ageing 
response, an age-induced reduction in the contractile performance of skeletal muscle 
has been frmly established [25,42,47], and strongly linked to reduced balance, reduced 
mobility and all-cause mortality [19,48–50]. An age-related reduction in muscle mass has 
been shown to occur as early as 25 years of age and is substantially lower in later life [51]. 
Muscle ageing is typically characterised as sarcopenia [25]; however, the loss of muscle 
mass and function is disproportionate, with the reduction in contractile function exceeding 
the loss of muscle mass or muscle cross-sectional area [52–55], with this phenomenon 
termed dynapenia [39]. In fact, the loss of strength has been shown to occur 2–5 times 
faster than the loss of mass [42], indicating that age-related muscle atrophy is prevalent 
much later in the ageing process and likely further accelerates the loss of muscle function. 
More specifcally increasing age is associated with a reduction in skeletal muscle qual-
ity [43,44,56], maximal force-generating capacity [24] and shortening velocity [47], which 
typically combine to result in a more severe loss of muscular power [57–59]. Muscular 
power is of greater importance to the completion of activities of daily living than muscle 
strength [60], with muscular power more strongly correlated with age-adjusted all-cause 
mortality than muscular strength [61]. Such changes in the above-mentioned contractile 
properties are evident across postural, locomotor and respiratory muscles [24,62,63], al-
though the magnitude of the response is infuenced substantially by numerous factors 
including physical inactivity, diet and disease [64,65]. One such confounding factor is obe-
sity, with evidence to suggest that excessive adipose tissue accumulation may exacerbate 
the age-related decline in muscle function [34,45,46]. 
Although to a relatively much smaller extent, and with greater ambiguity in fndings, 
there is a growing body of evidence to suggest that obesity independent of age results in 
a muscle-, sex- and contractile mode-specifc effect on skeletal muscle function [27–29]. 
Whilst a similar argument can be made for evidence examining the muscle ageing re-
sponse [43,44,56,66–69], experimental models examining the effects of high-fat diet (HFD) 
consumption on isolated skeletal muscle function have been important in developing our 
understanding of the effects of obesity on muscle structure [70] and function [18,37,71,72]. 
This method bypasses the impact of intramuscular fat during obesity and the effects of 
age on the neuromuscular activation of skeletal muscle [73] and thus allows one to assess 
muscle-specifc effects with more precise control of HFD nutritional composition and 
feeding duration [27], important factors that differ signifcantly between obese people. Fur-
thermore, studies employing isolated skeletal muscle models allow an accurate assessment 
of muscle quality, where contractile performance can be normalised to cross-sectional area 
(CSA) or mass of the muscle examined. Assessments of contractile function normalised to 
whole-body or segmental lean mass, typically as per the approaches adopted in whole-body 
in vivo testing in humans [31,34,36,74], have likely resulted in conficting conclusions with 
respect to obesity effects on muscle quality [27]. 
When the literature is considered holistically, and although highly specifc, previ-
ous work has indicated evidence for an obesity-induced increase in the absolute force-
producing capacity of antigravity muscles, a reduction in force to body mass ratio and 
a reduction in muscle quality [18,75,76]. Muscles with a faster fbre type composition 
likely show greater detrimental effects [18,37], with the response further dependant on the 
nutritional composition of the diet [71] and magnitude of adiposity. For example, Hurst 
et al. [37] examined the effect of 2, 4, 8 and 12 weeks of HFD feeding on the contractile 
performance of isolated mouse soleus, EDL or diaphragm muscle. Whilst muscle and 
contractile mode-specifc detrimental effects of HFD on measures of muscle quality and 
fatigue resistance were seen only after 8 weeks, correlations between gonadal fat pad mass 
and measures of contractile function indicated that irrespective of feeding duration, level of 
adiposity was an important factor dictating the magnitude of the HFD-induced response. 
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4. Age- and Obesity-Induced Mechanistic Changes Related to Altered Skeletal Muscle 
Contractile Function 
Based on the independent effects of ageing and obesity outlined above, one would 
expect that ageing and obesity together would exacerbate decrements in skeletal muscle 
function. This hypothesis is strengthened by examining the mechanistic characteristics 
associated with age- and obesity-induced changes in skeletal muscle function. Both have 
been robustly examined in previous reviews of the literature [23,25–27,77–81] and will 
be summarised here. Given the muscle- and contractile mode-specifc nature of both the 
muscle ageing response and the effects of obesity, mechanisms underpinning these changes 
are likely also muscle specifc. 
The age-related reduction in skeletal muscle function is multifactorial [23]. Some of 
the contributing factors are a reduction in the sarcoplasmic reticulum (SR) Ca2+ concentra-
tion, dihydropyridine receptor–ryanodine receptor uncoupling (i.e., excitation–contraction 
uncoupling) and reduced sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) activ-
ity [43,82,83] that all have a negative impact on muscle activation and relaxation. A reduced 
myogenic capacity and an increase in catabolic agents [23,84] result in a reduction in con-
tractile mass [52–54], particularly in fast fatigable muscle fbres [85]. Furthermore, ageing 
is associated with a reduced mitochondrial function [86] and increased heterogeneity of 
capillary spacing [87]. 
A HFD induced changes in muscle function similar to that seen in muscle ageing, with 
substantial HFD consumption linked to chronic low-grade infammation and a reduction in 
myogenesis [77,88–91], impaired excitation–contraction coupling [71,92], and a reduction 
in mitochondrial ATP regeneration [93]. However, HFD consumption has been linked to a 
shift towards a faster muscle phenotype [27], which appears to be at odds with the typical 
ageing response. 
Based on the independent effects of ageing and obesity, there appears to be a strong 
rationale to support the hypotheses that obesity has the potential to aggravate the age-
related reduction in skeletal muscle function. Herein, we provide a review of the evidence 
that has sought to address this question. 
5. Effects of Ageing and Obesity on Skeletal Muscle Contractile Function 
Evidence suggests that individuals that are both old and obese have compromised 
function in activities of daily living when compared to normal weight counterparts [2,94,95]. 
Whilst this in part may be attributed to kinematic differences brought about through local 
adipose tissue storage [96], joint pain [97], and impaired neurocognitive function [98], a 
signifcant contributor to these changes is likely related to the increased demand placed on 
skeletal muscle. Evidence examining the potential additive effects of ageing and obesity on 
the muscle function of older adults is limited and controversial (see Table 1). 
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Table 1. Summary of research examining the effects of obesity on the contractile performance of skeletal muscle in aged populations. 
Author Sex Participants: Group and Age (Age/Age Range; yrs) 
Absolute 
Contractile Performance Force to Body Mass Ratio Muscle Quality 
Body Composition and 
Muscle Morphological 
Measurements 









O IM KE (kg) and HGS (kg)↔ 
Y and Middle-aged Obese IM KE ↑ 
M: Y Obese HGS (kg) ↑ 
M: Middle-aged Left HGS (kg) ↔ Right HGS (kg) ↑ 
F: Y Obese Left HGS (kg) ↑ Right HGS (kg) ↔ 
F: Middle-aged Obese HGS (kg) ↑ 
Obese IM KE (Kg/kg −1) ↓ N/A N/A 
Pedersen et al. [32] M and F All participants (80) N/A 
M: IM TE, TF, EF, HGS and KE 
(N/ kg −1)↔ 
F: IM TE and TF (N/ kg −1)↔ 
F: BMI > 29 IM EF, KE and HGS 
(N/ kg −1) ↓ versus BMI < 24 
N/A N/A 
Rolland et al. [99] F 
Lean (80.7 ± 4.1) 
NW (80.2 ± 3.7) 
Obese (80.0 ± 3.5) 
Obese IM KE (N) ↑ versus lean 
Obese and NW IM KE (N) ↔ 
HGS (Nm2)↔ 
Obese IM EE (N) ↑ versus lean and NW 
-Sedentary Individuals IM KE (N) ↔ Irrespective of 
BMI * 
Active Obese IM KE (N) ↑ versus Active Lean * 
Active Obese and NW IM KE (N) ↔ * 
N/A N/A 
Obese FM and FFM (Kg and %) 
Total MM, leg MM and arm 
MM (Kg) ↑ 
Villareal et al. [35] M and F 
Non-obese non-frail (70.6 ± 0.8) 
Non-obese frail (77.3 ± 0.5) 
Obese (76.5 ± 0.9) 
Obese IK CON KE and KF (60 s−1; N.m) ↓ versus 
non-obese non-fail 
Obese and Non-obese frail IK CON KE and KF 
(60 s−1; N.m)↔ 
N/A Obese IK CON KE and KF torque p.u. LE LM (60 s−1; N.m/kg −1) ↓ 
Obese total fat (Kg and %) and 
FFM (%) ↑ 
Obese FFM (Kg) ↓ 
Hilton et al. [36] M and F Non-obese (58.0 ± 10.0) Obese (58.0 ± 9.2) 
IM DF and PF (N.m) ↓ 
IK CON PF and DF (60 s−1, 120 s−1; W) ↓ 
IK CON PF (60 s−1, 120 s−1; N.m) ↓ 
IK CON DF (60 s−1; N.m) ↓ 
IK CON DF (120 s−1; N.m)↔ 
N/A 
IK CON PF p.u. MV (60 s−1 , 
120 s−1;) W/cm3) ↓ 
IK CON DF p.u. MV 
(120 s−1; W/cm3) ↓ 
IK CON DF p.u. MV 
(60 s−1; W/cm3)↔ 
Distal LE IMAT volume (cm3) ↑ 
LE MV (cm3), adipose tissue 
volume (cm3) and muscle CSA 
(cm2)↔ 
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Table 1. Cont. 
Body Composition and Participants: AbsoluteAuthor Sex Force to Body Mass Ratio Muscle Quality Muscle Morphological Group and Age (Age/Age Range; yrs) Contractile Performance Measurements 
Paolillo et al. [33] F Non-obese (54.0 ± 11.0) Obese (58.0 ± 2.0) 
IK CON KE (60 s−1; N.m)↔ 
IK CON KE (300 s−1; W) ↑ 
IK CON KE (60 s−1; N.m/kg −1) ↓ 
IK CON KE (300−1; W/kg −1)↔ 
IK CON KE p.u. LM 
(60 s−1; N.m./kg −1) ↓ 
IK CON KE p.u. LM 
(300 s−1; W/kg −1)↔ 
BF (%), LM (kg), FM (kg) ↑ 
Choi et al. [34] M and F NW (70.0 ± 2.0) ** Obese (69.0 ± 2.0) ** 
IK CON KE (N.m) ↑ 
Type I single-fbre power (µN. FLs−1) ↓ 
Type I fbre maximal shortening velocity (FLs−1) ↓ 
Type I and IIa maximal Ca2+ activated force (mN) ↓ 
Type IIa single-fbre power (µN.FLs−1)↔ 
Type IIa fbre maximal shortening velocity 
(FLs−1)↔ 
IK CON KE (N.m/kg −1) ↓ 
IK CON KE p.u. thigh MV 
(N.m/cm3) ↓ 
Type I isolated fbre power p.u. fbre 
size (W/litre fbre) ↓ 
Type IIa isolated fbre power p.u. 
fbre size (W/litre fbre) ↔ 
Type I and IIa maximal Ca2+ 
activated force p.u. CSA (kN/m2) ↓ 
Total thigh volume (cm3), thigh 
fat volume (cm3), thigh MV 
(cm3), intramuscular fat 
volume (cm3), type I and IIa 
fbre CSA (µm2), type I fbre 
intramyocellular lipid ↑ 
Tomlinson 
et al. [100] F 
Y: UW (23.0 ± 6.7) 
NW (23.2 ± 7.9) 
OW (23.6 ± 8.0) 
Obese (30.9 ± 10.7) 
O: UW (63.8 ± 5.7) 
NW (63.5 ± 7.7) 
OW (68.2 ± 4.8) 
Obese (62.5 ± 9.0) 
Y Obese Net IM PF and IM PF (N.m) ↑ versus Y NW 
and UW 
Y Obese and OW Net IM PF and IM PF (N.m)↔ 
O Net IM PF and IM PF (N.m)↔ 
Y IM DF (N.m)↔ 
O Obese IM DF (N.m) ↑ 
Y activation and co-contraction (%)↔ 
O activation and co-contraction (%)↔ 
Y Obese IM PF (N.m/kg −1) ↓ 
O Obese IM PF (N.m/kg −1) ↓ 
versus O UW 
O Obese, OW and NW IM PF 
(N.m/kg −1)↔ 
Y Obese Net IM PF (N.m/kg −1) ↓ 
versus Y NW and UW 
Y Obese and OW Net IM PF 
(N.m/kg −1)↔ 
O Obese Net IM PF (N.m/kg −1) ↓ 
versus O NW 
N/A 
Obese BF (%), total BF and LM 
(kg) leg FM (kg) ↑ 
O Obese Leg LM (kg) ↑ versus 
O NW, UW and OW 
Y Obese Leg LM (kg) ↑ versus 
Y NW and UW 
Y Obese and OW Leg 
LM (kg) ↔ 
O Obese, OW and UW Net IM PF 
(N.m/kg −1)↔ 
Tomlinson Fet al. [101] 








Obese Net IM PF (N.m) ↑ versus NW and UW 
Obese and OW Net IM PF (N.m) ↔ 
High BF Net IM PF (N.m) ↑ versus normal BF 
Obese Net IM PF p.u. MV 
(N.m/cm3) ↓ versus NW 
Obese, UW and OW Net IM PF p.u. 
MV (N.m/cm3)↔ 
Obese GM-specifc force (GM 
fascicle force/PCSA) ↓ versus NW 
N/A and UW 
Obese and OW GM-specifc force 
(GM fascicle force/PCSA) ↔ 
High BF GM-specifc force (GM 
fascicle force/PCSA) and Net IM PF 
p.u. MV (N.m/cm3) ↓ versus 
normal BF 
Obese MV (cm3) ↑ 
High BF MV (cm3) ↑ versus 
normal BF 
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Table 1. Cont. 
Author Sex Participants: Group and Age (Age/Age Range; yrs) 
Absolute 
Contractile Performance Force to Body Mass Ratio Muscle Quality 
Body Composition and 
Muscle Morphological 
Measurements 
Tibana et al. [102] F Non-obese (68.0 ± 6.2) Obese (66.5 ± 5.0) 
Leg press, bench press (kg) ↔ 
Bicep curl (kg) ↑ N/A N/A 
Obese WC (cm), NC (cm), W:H, 
BF (% and kg), FFM (kg) ↑ 
Erskine et al. [103] MandF 
Y: Normal BF (24.0 ± 8.4) 
High BF (28.9 ± 9.7) 
O: Normal BF (65.5 ± 8.0) 
High BF (66.0 ± 7.3) 
High BF IM PF (N.m) ↑ 
IK CON PF (60 s−1; N.m)↔ 
High BF GM fascicle force (N) ↑ 
High BF activation capacity (%) ↓ 
High BF IK CON (60 s−1) and IM PF 
(N.m. kg −1) ↓ 
GM-specifc force (GM fascicle 
force/PCSA) ↔ 
High BF IK CON (60 s−1) and IM PF 
p.u. MV (N.m/cm3) ↓ 
Y normal BF IK CON (60 s−1) and 
IM PF p.u. MV (N.m/cm3) ↑ versus 
all other groups 
GM fascicle length ↔ - High BF 
GM FPA, FM (kg), LM (kg), 
GM volume (cm3), GM PCSA 
(cm2)↑ 
Abbreviations: BMI, body mass index; M, male; F, female; Y, young; O, old; NW, normal weight; UW, underweight; OW, overweight; IM, isometric; IK, isokinetic; CON, concentric; KE, knee extensors; EE, elbow 
extensors; EF, elbow fexors; TF, trunk fexors; TE, trunk extensors; PF, plantar fexor; DF, dorsi fexor; GM, gastrocnemius medialis; HGS, hand grip strength; FM, fat mass; FFM, fat-free mass; MM, muscle mass; 
MV, muscle volume; BF, body fat; LM, lean mass; LE, lower extremity; IMAT, intramuscular adipose tissue; CSA, cross sectional area; PSCA, physiological cross sectional area; FPA, fascicle pennation angle; W, 
watts; WC, waist circumference; NC, neck circumference; W:H, waist to hip ratio; N/A, not applicable; p.u., per unit; Net, sum of maximal torque and co-contraction torque; data presented as the mean ± SD; * 
contractile function adjusted for physical activity; ** data presented as the mean ± S.E.M; ↓/↑ P<0.05, ↔ no change/difference. 
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Similar to observations in young obese individuals [75], there is evidence that obe-
sity may also result in an increased absolute force of locomotor and postural muscles of 
older adults [99,104], whilst non-antigravity muscles are unaffected [99]. This increase in 
absolute muscle force-generating capacity has been attributed to increased loading of the 
musculoskeletal system as a result of supporting and ambulating a greater load [27]. Other 
studies, however, show that in older adults there is no such obesity-related increase in 
absolute force-generating capacity [31,33,100,105,106] and in some cases, obesity has even 
been reported to result in a reduced absolute force-producing capacity of the musculature 
of older adults [36,105]. The disparity in response between young and old obese groups 
may in part be explained by an age-induced reduction in myogenesis [107], limiting the 
adaptations that may occur through elevated loading. 
Whatever happens with the absolute force-generating capacity, like in young adults, 
there is evidence that the force to body mass ratio is signifcantly lower in obese older 
adults compared to normal weight counterparts [31,33]. A reduction in the force to body 
mass ratio will have effects that are more substantial for older adults where functional 
mobility may be already compromised. Conversely, Tomlinson et al. [100] rejects these 
trends indicating no difference in peak isometric force of the plantar fexors muscles relative 
to body mass between old obese and age-matched lean equivalents, concluding that there 
may be a potential protective effect in old compared to young obese. 
Given that both ageing and obesity effects on skeletal muscle function are likely infu-
enced by several factors, a lack of homogeneity in the sampled participants may account 
for the disparity in results. For example, Tomlinson et al. [100] demonstrated that obese 
aged participants displayed a trend for an increase in peak torque of the plantar fexors and 
reduced force to body mass ratio at a level that did not reach statistical signifcance. Both 
ageing and obesity responses are likely infuenced by physical activity, diet, comorbidi-
ties, regional adipose tissue accumulation and magnitude and duration of adipose tissue 
accumulation [27,64,65,108,109], which may account for a high degree of variation in the 
population sampled and makes it diffcult to make direct comparisons between published 
work. Furthermore, summarising current evidence is challenging given the broad range 
of ages examined (58–80 yrs), the limited focus on older and geriatric age groups and a 
disproportionate focus on female participants compared to males. 
It is frmly established that reduced physical activity contributes to the age-related 
decline in contractile performance [24]. Given that obesity may result in a decrease in phys-
ical activity levels [110], it is a challenge to distinguish between obesity-induced changes 
in contractile function and those that result from physical inactivity. Surprisingly, few 
studies examining the additive effects of age and obesity have measured or controlled for 
physical activity. When adjusted for height, physical activity, pain, depression, and muscle 
mass, Rolland et al. [99] demonstrated that in older women, obesity-induced increases in 
hand grip strength, peak isometric force of the elbow extensors and peak isometric force 
of the knee extensors for the sedentary group, were no longer apparent. However, higher 
peak isometric torque of the knee extensors was still prevalent in the obese active group 
compared to the active lean control. Interestingly, Paolillo et al. [33] also indicated no 
difference in peak concentric torque of the quadriceps muscles in obese postmenopausal 
women compared to a normal weight group matched for age and anaerobic capacity. 
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Based on the presented evidence, an aggravated decline in the functional performance 
of old obese individuals may be explained by a reduction in the force to body mass ratio, 
what is less clear from the available evidence is the impact of obesity on the intrinsic 
force-producing capacity of muscle. In vivo studies examining obesity effects of muscle 
quality have resulted in ambiguous fndings [28,30] and studies specifcally examining 
the additive effects of obesity and ageing are sparse. There is some evidence to indicate 
that muscle performance normalised to whole-body or regional lean mass is signifcantly 
reduced in old obese adults [33,106]. Using a biopsy of the vastus lateralis, Choi et al. [34] 
demonstrated that power normalised to fbre CSA was signifcantly reduced in type I fbres 
of obese older adults when compared to normal-weight controls. Such evidence supports a 
muscle fbre type-specifc, obesity-induced reduction in muscle quality. 
6. Effects of Ageing and Obesity on Contractile Function of Isolated Rodent 
Skeletal Muscle 
Whilst there is a growing body of work examining the effects of HFD on isolated 
skeletal muscle function [27], only a small number of studies have examined the combined 
effects of ageing and HFD (see Table 2 for a complete summary of results). Abrigo et al. [111] 
demonstrated that 12-week old male C57BL/10J mice fed a HFD for 38 weeks had lower 
absolute strength and strength relative to body mass when assessed in vivo. Furthermore, 
the HFD fed mice had reduced specifc force (force relative to muscle CSA) of the tibialis 
anterior across a range of stimulation frequencies. By contrast, Bott et al. [112] showed 
that the consumption of a HFD for 13 weeks did not signifcantly diminish the specifc 
force of EDL and soleus isolated from 33-week-old male C57BL/6J mice when compared to 
age-matched controls. HFD consumption did, however, result in increased CSA of soleus, 
supporting the idea of a HFD-induced hypertrophy of the postural muscles. Whilst the 
disparity in fndings for measures of specifc force may be accounted for by substantial 
differences in HFD feeding duration, it should also be considered that the aged model used 
by Abrigo et al. [111] and Bott et al. [112] might not be the most suitable for determining 
the additive effects of HFD consumption and ageing on skeletal muscle function. The 50-
and 33-week-old mice used in these studies may represent an early ageing response [43] 
and are much younger than 18–24 months age groups typically used in studies examining 
effects of muscle ageing [113]. In the work by Bott et al. [112], other than an age-induced 
increase in isometric relaxation time, ageing had no other effects on contractile function of 
the EDL. As such, these fndings may not refect the effects of HFD consumption on the 
contractile performance of muscles extracted from older animals. 
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Table 2. Summary of studies examining the effects of obesity on isolated muscle contractile function in aged rodents. 
Author Animal Information Dietary Protocol Experimental Protocol Absolute Contractile Performance 
Muscle Quality 
(Contractile Parameter Per 
Unit of Tissue Size) 
Body Composition and Muscle 
Morphology Measurements 
Abrigo et al. [111] 
M C57BL6/10 mice aged 
12 weeks 
Groups: Control HFD 
38-week diet 
Control calorie (%):fat, 10; 
CHO, 70; protein, 20 
HFD calorie (%): fat, 60; 
CHO, 20; protein, 20 
In vivo: forelimb strength 
via weightlifting links of 
mass 15.5–54.1 g 
In vitro: IM tetanus force of 
whole TA using stim. freq. 
10–150 Hz at room temp. 
In vivo strength ↓ in HFD 
In vivo strength p.u. body 
mass ↓ in HFD 
Tetanic stress p.u. muscle 
CSA (mN/mm2) ↓ in HFD 
at all stim. freq. 
Type IIa distribution (%) ↑ 
in HFD 
Type IIb distribution (%) ↓ 
in HFD 
Percentage of fbres with a 
larger diameter (µm) ↓ in HFD 
SOL: Twitch and tetanus 
Bott et al. [112] 





Control calorie (%):fat, 10.3; 
CHO, 75.9; protein, 13.7 
HFD calorie (%): fat, 45.3; 
CHO, 40.8; protein, 13.8 
IM twitch and tetanus force 
of whole SOL and EDL at 
25 ◦C 
activation time (mN/ms) ↔ 
Twitch relaxation time↔ 
Tetanus relaxation time ↓ in 
HFD compared to baseline 
EDL: Twitch activation and 
relaxation time ↑ in HFD 
compared to baseline 
Tetanus activation time↔ 
Twitch and tetanus stress 
p.u. muscle CSA 
(mN/mm2)↔ across 
all groups 
SOL: Type I, IIa, IIx and IIb CSA 
(µm2) ↑ compared to control 
and baseline 
EDL: Type IIa and IIb ↓, type IIx 
↑ compared to baseline Type IIa 
↓, IIx ↔ and IIb ↓ compared 
to control 
Tetanus relaxation time ↓ in 
HFD compared to baseline 
IM stress p.u. muscle CSA 
(kN.m2)↔ for SOL and Activation and relaxation BM (g), circumference (cm), 9-week self-selected diet EDL, tendency for ↓ inF CD-1 mice aged 70 weeks IM tetanus force; WL power (ms) ↔ for all muscles BMI, gonadal FM (g), and Control calorie (%): fat, 7.4; HFD DIA Groups: and fatigue resistance of IM force (mN) ↔ for all FM:BM ↑ in HFD Hill et al. [45] CHO, 75.1, protein, 17.5 WL power p.u muscle mass Control whole SOL, EDL and DIA muscles MM (mg) and CSA (m2) ↓ inHFD calorie (%): fat, 63.7; ↔ for SOL and EDL, ↓ forHFD at 37 ◦C WL power ↑ for HFD soleus HFD SOL and EDL CHO, 18.4; protein, 17.9 HFD DIA and EDL MM:BM, ↔ for SOL and EDL WL fatigue resistance ↔ for 
all muscles 
20-month diet SOL: IM force (mN) ↔ at all SOL: IM stress p.u. muscle BM (g), Abdominal visceral fat M C57BL/6 mice aged Control calorie (%): fat, 5.6; IM tetanus force of whole stim. freq. Activation and CSA (kN.m2)↔ at all stim. (g), EDL IMCL droplet size Eshima et al. [46] 2 months CHO, 53.8; protein, 22.6 SOL and EDL using relaxation time (ms) ↔ freq. (µm2) ↑ in HFD Groups: Control HFD HFD calorie (%): fat, 60; stim. freq. 1–150 Hz EDL: IM force ↓ in HFD at EDL: IM stress p.u. muscle SOL and EDL MM (mg) ↔CHO, 20; protein, 20 50–150 Hz CSA ↓ in HFD at 50–150 Hz 
Abbreviations: M, male; F, female; HFD, high-fat diet; CHO, carbohydrates; TA, tibialis anterior; EDL, extensor digitorum longus; SOL, soleus; DIA, diaphragm; stim. freq., stimulation frequency; IM, isometric; 
WL, work loop; CSA, cross-sectional area; BMI, body mass index; BM, body mass; MM, muscle mass; FM, fat mass; FM:BM, fat mass to body mass ratio; MM:BM; muscle mass to body mass ratio; IMCL, 
intramyocellular lipid; p.u., per unit. ↓/↑ p < 0.05,↔ no change/difference. 
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Hill et al. [45] later demonstrated that HFD consumption aggravated the age-related 
decline in the contractile function of respiratory muscle with limited effects on locomotor 
muscle performance (Table 2). Using 79-week-old female CD-1 mice, a model that has 
a substantial age-related decline in muscle function [56], 9 weeks HFD resulted in an 
increased muscle mass and maximal absolute work loop power for whole soleus and 
EDL muscle. Peak isometric force, specifc force, work loop power normalised to muscle 
mass and fatigue resistance were unchanged. These fndings would appear to, in part, 
contradict previous work using a similar methodological approach to examine skeletal 
muscle contractile performance in young HFD-fed rodents [18,37]. In contrast to the EDL 
muscle, isometric stress and work loop power normalised to muscle mass were reduced in 
the diaphragm of HFD group, indicating that obesity caused a muscle-specifc aggravation 
of the typical ageing response. A reduction in diaphragm function may have consequences 
for lung function and respiratory disease risk [114,115]. Whilst this work offers insight into 
the combined effects of age and obesity, generalisability of these data should be treated with 
caution. The large changes in body composition over a relatively short time period may 
not represent the pattern of changes in body composition over the life course. Furthermore, 
whilst the body mass and gonadal fat mass (FM) were larger in HFD than control mice, the 
control group used in this study had substantially greater adiposity than controls used in 
comparable young rodent studies as a result of the typical ageing process [18,37]. While it 
is not possible to rule out that obesity did not contribute already to the age-related decline 
in muscle function seen in the control group, it does show that additional HFD-induced 
increases in FM may be detrimental to the contractile performance of specifc skeletal 
muscle. Based on previous work in young rodent models, it may be assumed that the 
demonstrated obesity effects would be more substantial if comparisons were made to a 
lean control [37]. 
Eshima et al. [46], examining the effect of 20-month HFD feeding on the contractile 
performance of whole soleus and EDL muscle from male C57BL6J mice, addresses some 
of these issues. Chronic HFD consumption and the associated increase in body mass 
more likely to refect those seen in obese humans. Furthermore, the lean control group 
used as a comparator did not display a signifcantly different body mass or abdominal 
visceral FM to that of a younger 6-month-old lean control group. Whilst an increase 
in age resulted in a decrease in specifc force for the EDL across a range of stimulation 
frequencies, both specifc and absolute force of the 20-month HFD-fed mice was reduced 
compared to the age-matched lean control. Such trends were similar to EDL isolated 
from 4-week HFD-fed mice when compared to an age-matched lean equivalent, with 
the HFD-induced reduction in contractile function in part attributed to dysfunction in 
intracellular Ca2+ release. Conversely, neither age nor HFD signifcantly infuenced the 
contractile performance of the soleus muscle, similar to previous work [45]. Such fndings 
for the soleus muscle are diffcult to evaluate in the context of potential additive effects 
of both ageing and increased adiposity, as there was no age-associated reduction in the 
soleus performance. 
Although the varied methodological approaches and likely sex, age, HFD-feeding 
duration and contractile mode-specifc response [18,27,37,46,116] make direct comparisons 
challenging, evidence indicates that HFD consumption exacerbates the age-related decline 
in muscle function and that the HFD response in older muscles may differ to that seen 
in younger counterparts. Limited evidence makes it diffcult to determine if the severity 
of excessive adipose tissue accumulation on muscle function is either greater or less 
substantial in aged muscles. The only study to make direct comparisons between HFD 
effects on isolated muscle function from young and old mice indicates that these were 
similar in young and old rodents [46]. When considered collectively, work from the Tallis 
et al group indicates that HFD consumption is more detrimental to locomotor muscle 
quality at younger age groups compared to older, whilst HFD effects on the diaphragm are 
similar [18,37,45]. 
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7. Sex-Specifc Effects of Obesity on the Age-Related Loss of Skeletal Muscle 
Contractile Function 
The age-associated reduction in muscle contractile function is apparent in both men 
and women. It is clear, however, that at peak physiological maturity, men typically show 
higher levels of absolute power, power relative to body mass and specifc power than 
women [117]. There is some suggestion that the absolute and relative loss of absolute and 
specifc contractile function is faster in men compared to women [117]. While the general 
consensus is indeed that the age-induced loss of absolute strength [52,54,118–120] and 
power [57,121] is greater for men than women, it should be noted that the relative decline 
is similar and that the larger absolute decline in men is just a consequence of the higher 
starting point [59] In line with this, studies that show no difference in the magnitude of the 
decline in absolute force and power between males and females [55,118,122,123] are talking 
about the relative decline in muscle function. For example, McPhee et al. [55] showed that 
both younger and older men had greater absolute knee extensor torque and physiological 
cross-sectional area (PCSA) of the quadriceps than women, the relative magnitude of the 
decline in contractile function and quadriceps PCSA was similar between men and women. 
Likewise, there is little evidence for sex-specifc effects of obesity-induced changes in 
contractile function of aged muscle. In young adults, obesity induces sex-specifc changes 
in FM: fat-free mass (FFM) ratio. Lafortuna et al. [76] reported that there is a concomitant 
increase in the FM and FFM in obese men, while in obese women FM increased but changes 
FFM were limited. Despite these differences, obesity-induced changes in muscle function 
were comparable in men and women. Lafortuna et al. [124] further demonstrated that after 
adjusting for age, muscle volume increased to a greater extent in obese males compared 
to female counterparts. However, only Miyatake et al. [31] has directly compared the sex-
specifc effect of obesity on aged skeletal muscle function, demonstrating that obesity effects 
of grip strength and absolute and normalised knee extensor strength were comparable 
between males and females. 
Irrespective of age, previous work examining the sex-specifc effects of HFD on 
isolated skeletal muscle contractile function are also sparse. For the most part, studies are 
constrained to a single-sex and comparisons between published works is challenging given 
the varied methodological approaches [27]. No study has yet considered the sex-specifc 
effects of HFD and ageing on isolated skeletal muscle function (Table 2). It is therefore not 
yet possible to robustly determine if the effects of obesity on the muscle ageing response 
are sex specifc, highlighting an important area for future investigation. 
8. Consequences for Functional Performance 
Unlike in human experiments, there is a much clearer trend for an increase in absolute 
force and power-producing capacity of postural and locomotor musculature in studies that 
have examined the additive effects of ageing and HFD in rodent isolated muscle [45,46]. 
However, this seemingly positive adaptation does not correspond with the magnitude of 
the increase in body mass [45,46]. When the available evidence is considered holistically, 
both a reduction in force to body mass ratio and muscle quality likely contribute to the 
impaired functional performance seen in obese older adults [125–127]. More specifcally, 
old obese individuals have been shown to have reduced postural control, a slower more 
tentative gait pattern, increased knee joint loading and altered movement patterns during 
the completion of activities of daily living, potentially exacerbating musculoskeletal injury 
risk [128–133]. Whist these biomechanical differences may be related to kinematic changes 
brought about via a change in the position of the centre of mass and restricted joint range 
of motion [134], the evidence presented here indicates that an accelerated obesity-induced 
reduction in skeletal muscle function is likely a substantial contributor to these changes. 
We have summarised the effects of old age and obesity on the contractile performance 
of locomotor muscles in Figure 1. We have also considered how this contributes to the 
negative cycle of obesity, whereby poorer contractile function reduces the ability to perform 
activities of daily living, which in turn reduces the level of physical activity in old obese 
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adults and leads to further reductions in contractile performance, with the overall effect 
being a reduced quality of life. 
Figure 1. Schema outlining the effects of old age and obesity in isolation on absolute and normalised contractile function 
and their combined effects on contractile performance in old obese adults. Arrows demonstrate the direction of the effect 
on contractile performance, where an upwards arrow shows an increase (↑), a downwards arrow a decrease (↓), and a 
sideways arrow (↔) indicating little change. A greater number of arrows indicates a greater magnitude of the effect. The 
negative cycle of obesity in old obese adults is demonstrated, resulting in a reduced quality of life. 
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Compared to normal-weight counterparts, old obese individuals may be at greater risk 
of musculoskeletal injury given the importance of adequate muscle function for maintaining 
joint stability and absorbing impact forces [135–137]. For example, old obese individuals 
have greater fall risk [138,139], with muscular strength recognised as an important facet of 
postural control [140,141]. Furthermore, the impact of musculoskeletal injury may be more 
severe in old obese adults, as discussed in more detail below. 
Those with age-induced impaired muscle function and obesity have been shown to 
have a greater risk of metabolic syndrome, cardiovascular disease, diabetes and all-cause 
mortality [15–17]. In part, an obesity-induced accelerated loss of skeletal muscle function 
with increasing age may act to catalyse poor health outcomes, given a healthy skeletal 
muscle phenotype is needed to regulate metabolism and for physical activity. Such effects 
may not solely be associated with altered locomotor muscle function. An obesity-induced 
accelerated loss in diaphragm function in older age, as reported by Hill et al. [45] in mice, 
may impair respiratory function, physical activity, lipid oxidation and contribute to the 
associated higher risk of respiratory disease in old obese individuals [142]. 
9. Future work and Potential Target Therapeutic Strategies for Intervention 
As previously outlined, research examining the combined effects of obesity and ageing 
on skeletal muscle function is sparse and more work is needed to further our understating 
in this area. Whilst ageing results in the loss of isometric and concentric muscle function, 
eccentric muscle function is relatively well preserved [47]. The combined effects of ageing 
and obesity on eccentric function are yet to be explored. Eccentric muscle activity is 
important for deceleration, stabilisation and absorbing impact [143], thus is imperative for 
the safe completion of activities of daily living and in mitigating musculoskeletal injury. 
Obesity effects on eccentric muscle function may, like in ageing, not be analogous to those 
seen for concentric and isometric function. Mechanistically, eccentric force production 
differs from other contractility modes and is believed to be reliant on a high rate of 
reattachment of stretched cross-bridges [144] and on the active stiffening of the giant 
protein titin [145–147]. Obese individuals likely have a greater reliance on high-intensity 
eccentric contractions given the requirement to control a larger load. These physiological 
and biomechanical differences provide a rationale for further investigation. 
Furthermore, short-term muscle disuse is associated with a catabolic crisis, likely 
resulting in an accelerated trajectory of functional decline in older adults [148]. For example, 
short-term bed rest (< 10 days) has been shown to decrease muscle mass and strength in 
young and older adults [149,150]. Limb suspension and immobilisation in rodent models 
support this idea [151–153] but have further indicated that the recovery of mass and 
strength in old muscle following reloading is prolonged [154]. Such changes in muscle 
function likely have profound effects on the safe completion of activities of daily living, and 
these consequences may be exaggerated in old obese individuals (Figure 2). Obesity may 
aggravate the age-induced reduction in myogenesis [23,77], resulting in a more substantial 
catabolic crisis than that seen with ageing alone. Furthermore, impaired myogenesis may 
account for the prolonged recovery from skeletal muscle damage seen in both HFD and 
ageing rodent models [155,156]. Future work should consider developing an understanding 
of the combined effects of obesity and ageing on catabolic crisis models and injury recovery, 
particularly given the elevated risk of chronic health conditions in the older population. 
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Figure 2. Proposed model of age-related loss in skeletal muscle function relative to body mass accelerated by acute illness 
or injury. The accelerated loss of function and incomplete recovery has more profound consequences for obese older adults 
leading to earlier onset of low physical function and disability (MVC, maximal voluntary contraction; BM, body mass; 
fgure adapted from [10,148]). 
Given the potential for the deterioration of muscle function to be exaggerated in older 
obese adults, effective therapeutic strategies to offset these detrimental effects should be 
considered. In older adults, there is solid evidence for the benefts of resistance training 
on skeletal muscle function for both old [157,158] and old obese adults [159,160]. Whilst 
both calorifc restriction and exercise are regularly prescribed as a means to reduce obesity, 
these interventions have poor adherence [161]. In fact, Fildes et al. [162] demonstrated that 
current nonsurgical obesity treatment strategies are failing to achieve sustained weight 
loss in the majority of obese patients, with data indicating that the annual probability of 
patients with obesity attaining a normal body weight being < 1%. Calorifc restriction 
is the most effective method of reducing body mass [163]. However, concurring loss of 
both adiposity and lean mass may occur [164] potentially resulting in a further reduc-
tion in muscle performance [165] a particular risk for older adult populations. Ensrud 
et al. [166] indicated that intentional weight loss in overweight older women increased the 
risk of hip fracture, which may be linked to both a reduction in lean mass and a reduced 
bone mineral density through calorie restriction [167]. Furthermore, recent work has indi-
cated that while calorifc restriction may be effective at reversing HFD-induced changes 
in skeletal muscle metabolism of zebrafsh, such an intervention may not be suffcient to 
reverse changes in contractile performance [72]. Whilst there is evidence to support the 
effectiveness of well managed dietary interventions in older adults [168], it is not clear 
if the risks associated with calorie restriction in older adults outweigh the benefts [169]. 
Conversely, a progressive programme of physical activity may be benefcial for manag-
ing body composition [163,164,170] and maintaining muscle function [159,160]. However, 
poor adherence indicates a demand for low-cost alternatives strategies to improve muscle 
function. Such outcomes may be achieved via chronic supplementation of dietary sup-
plements. Although not an exhaustive list, dietary supplementation of vitamin D and 
Resveratrol have shown promise, but are yet to be robustly explored for their potential to 
reduce or reverse the additional negative impact of obesity on the age-related decline in 
muscle function. There is more robust support for benefts of dietary protein supplementa-
tion to combat muscle ageing, but its effectiveness in the old obese population is not yet 
established. Below, we consider evidence that may stimulate further study of these dietary 
supplements in the treatment of muscle weakness in the older obese person. 
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9.1. Vitamin D 
Vitamin D (or in its biologically active form 1α,25(OH)2D3, 24R,25-dihydroxyvitamin 
D3 [24R,25(OH)2D3]) has been demonstrated to play an important role in skeletal muscle 
function, with vitamin D defciency associated with a reduction in the force-producing 
capacity of skeletal muscle [171–173], increased fall risk [173–175] and a reduction in physi-
cal function [173]. Prolonged supplementation of vitamin D has been shown to improve 
skeletal muscle function in older adults [176,177], and in young healthy and young athletic 
individuals [178–181], irrespective of weight status. Such effects are largely apparent in 
individuals that demonstrate a vitamin D defciency. Obesity has been shown to cause 
vitamin D defciency [182,183], attributed not only to altered behaviour and lower dietary 
intake but also to reduced synthesis, a reduced intestinal absorption, altered metabolism 
and elevated accumulation in FM [184,185]. As such, vitamin D defciency may mechanis-
tically account for at least some of the obesity-associated decrements in muscle function, 
thus potentially making supplementation an appropriate target for intervention. Through 
interaction with vitamin D receptors, which are expressed ubiquitously including in skele-
tal muscle [182], vitamin D likely evokes both systemic and direct muscle effects which may 
account for the improvement of skeletal muscle function seen in vivo with vitamin D sup-
plementation. There is evidence that vitamin D improves mitochondrial function, muscle 
insulin signalling, contractile protein synthesis, calcium and phosphate homeostasis and 
infammation [184,186–188], factors which are imperative for optimal contractile perfor-
mance. Interestingly, many of these responses counteract the effects elicited by both ageing 
and HFD in skeletal muscle function [25,27]. Despite some ambiguity, there is also evidence 
that vitamin D supplementation may reduce body fat in obese individuals [189–191]. Low 
serum 25(OH)D has been associated with elevated parathyroid hormone (PTH) and low 
intracellular Ca2+, which may contribute to obesity due to elevated lipogenesis and sup-
pressed lipolysis [185]. High levels of adiposity, brought about through a positive energy 
balance, result in elevated intramuscular lipid accumulation [70] and higher visceral fat, 
both of which are likely major contributors to the HFD-induced reduction in muscle quality. 
Intuitively, a vitamin D-induced reduction in stored lipids may evoke improved muscle 
function, attenuating or even to some extent reversing the response previously outlined. 
Interestingly, vitamin D supplementation has displayed anti-obesogenic effects in mice, 
where the administration of vitamin D to HFD-induced obese mice halted the progression 
in body weight gain, hyperglycaemia and hyperinsulinemia induced by diet [192]. 
9.2. Resveratrol 
Resveratrol (3,5,40-trihydroxystilbene), a natural polyphenol compound sourced in 
trace amounts from grapes, berries and nuts, has received attention for its potential to 
alleviate some of the health consequences associated with several metabolic diseases, 
including obesity [193,194]. Supplementation with resveratrol has shown to attenuate 
some of the detrimental changes that contribute to poor skeletal muscle health in obese 
individuals [195–197]. In obese rodent models, resveratrol has shown to both limit and halt 
overall, segmental and intramuscular adipose accumulation [195–198]. These effects have 
largely been attributed to reduced activity of enzymes involved in fatty acid synthesis and 
triacylglycerol accumulation in adipose tissue and down-regulated mRNA expression of 
genes related to the lipogenic pathway [198–200]. Furthermore, evidence indicates that 
resveratrol mitigates obesity-induced low-grade chronic infammation and reduce AMPK 
activity [195,197]. Resveratrol may further enhance both size and density of mitochon-
dria [196] and promote myogenesis [201], which may ultimately culminate in improved 
skeletal muscle contractile function. 
Whilst ambiguity exists with respect to the benefts of resveratrol in humans, given 
the low bioavailability of the compound, it would still appear to elicit positive health 
benefts [202,203]. The ambiguity in human trials is likely a result of methodological differ-
ences between studies, primarily the combination of dose and duration. Ambiguity also 
exists with the potential therapeutic effects of resveratrol for mitigating declines in muscle 
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mass [204]. Resveratrol provides a protective effect on muscle mass during mechanical 
unloading in young rodents [205], yet little effect in aged rodents [206,207]. However, 
recovery of muscle mass following unloading may be enhanced in older muscle when 
supplemented with resveratrol [206]. Further evidence reports that resveratrol treatment 
does not reduce an age-related decline in muscle mass [208], but supplementation may be 
effective in aged muscle when combined with exercise [209]. Whilst further work is needed 
to assess the effcacy of resveratrol in the context of ageing and obesity, there is evidence to 
suggest the outlined changes can translate to improved skeletal muscle contractile function 
and exercise performance across multiple rodent models [196,204,210–213]. 
9.3. Protein 
Given its anabolic and appetite-suppressing effects [214–216], dietary protein may be 
an important macronutrient to combat the additive effects of age and obesity on skeletal 
muscle function. Optimising the protein or essential amino acids intake in old age has 
been demonstrated to improve muscle protein accretion [217]. Low protein intake in 
older adults has been associated with an accelerated loss of lean mass [218,219], grip 
strength [220] and an enhanced risk of developing mobility limitations [221]. Furthermore, 
results from meta-analysis indicate that low protein intake is associated with frailty [222]. 
Such fndings justify increasing dietary protein and essential amino acid intake to combat 
the age-related decline in skeletal muscle function, a topic that has been the subject of 
several meta-analyses. 
When combined with an exercise intervention, primarily resistance training, there is 
strong support that increasing protein intake in older adults will cause a superior increase 
in lean mass, leg strength, and some aspects of physical function [223–225]. Effects of 
increased protein intake in the absence of resistance exercise appear controversial. Whilst 
the results of some meta-analyses indicate increased strength, lean mass and physical 
function [226,227], others have shown no effects [228–230]. The disparity in fndings 
may relate to several factors. It has been suggested that increasing protein intake may 
have a greater beneft for frail older adults [223,224], those with low habitual protein 
intake [226] and for men [223]. Furthermore, there is still debate regarding the optimal 
quantity, distribution and source [231], highlighting a need for more systematic studies. 
Irrespective of age, high protein diets have an important role in weight manage-
ment, attenuating the loss of lean mass that may occur as a result of calorie restricted 
diets [214,232,233]. Furthermore, the additive effect of protein supplementation and re-
sistance training for increasing lean mass and lower limb muscular strength, reported 
in a meta-analysis by Liao et al. [223], was equivalent in a high BMI (>30 kg/m2) group. 
Interestingly, however, there is some suggestion that the protein-induced prevention of 
age-related lean mass loss varies depending on obesity status [234]. 
Preserved or increased lean mass evokes obvious benefts given its association with 
muscle function, but there is a need for future work to consider the impact on muscle 
quality. In particular, focus on branched-chain amino acids such as leucine and β-hydroxy-
β-methylbutyrate (HMB), a key metabolite of leucine, have shown promise [235]. 
9.4. Pharmacological Interventions 
The aforementioned strategies are relatively cost-effective methods for treating obesity. 
In some cases, however, traditional methods for treating obesity in young and old adults 
may not be viable either due to other underlying debilitating factors or poor adherence to a 
treatment regimen. Pharmacological interventions may therefore be required for improving 
muscle morphology and contractile function, or the weight status of obese individuals. 
Many pharmacological treatments are available to treat sarcopenia, targeting improve-
ments in muscle mass, muscle contractile function and performance of activities of daily 
living [236,237]. However, comparatively fewer pharmacological treatments have been 
identifed for specifcally treating older adults with low muscle mass and high FM [238,239]. 
Given the cross-over between the mechanisms that result in the deleterious effects upon 
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muscle morphology and function, some pharmacological agents are available which have 
been used to independently treat both sarcopenia and obesity in old age [236,238]. There-
fore, the pharmacotherapies considered here will only pertain to those which have been 
examined in both sarcopenic and old obese populations, namely myostatin inhibition and 
hormone replacement therapy via testosterone provision. 
Myostatin is part of the transforming growth factor beta family which is primarily 
responsible for negatively regulating muscle mass. A recent review has identifed that 
myostatin may play an important role in contributing to the negative cycle of obesity by 
not only adversely regulating muscle mass but also reducing lipid oxidation and insulin 
sensitivity [239]. Myostatin inhibitors and myostatin deletion in rodents has not only shown 
to increase muscle mass [240,241], but also protect against the negative effects of obesity 
by preventing insulin resistance and accumulation of body fat, and enhancing fatty acid 
oxidation [239,242–244]. However, studies examining contractile function have reported 
that myostatin deletion caused the specifc tension of both in situ [245] and isolated skeletal 
muscles to be signifcantly poorer than normal mice despite inhibition causing signifcant 
muscular hypertrophy [240,241]. In humans, very little work has examined the effects of 
myostatin inhibition in old obese populations, with work primarily focusing on dystrophic 
adults [246]. One recent study examined myostatin inhibition via the provision of a single 
dose of bimagrumab to old obese adults which resulted in signifcant increases in thigh 
muscle volume and lean body mass, as well as reductions in body mass, whilst muscle 
strength remained unchanged [247]. 
Another proposed pharmacological approach is hormone replacement therapy, specif-
ically testosterone replacement [236,238,248]. Testosterone is an androgenic hormone that 
stimulates muscle anabolism, activates satellite cells [249] and reduces FM [250–252]. Age-
ing is associated with a natural decline in testosterone levels in men, up to 1% per year 
from the age of 30 [253], which leads to a reciprocal reduction in muscle mass, muscle 
strength and fat-free mass [254] that is exacerbated in old obese adults with low testos-
terone [255]. The effects of testosterone replacement in the treatment of sarcopenia and 
obesity have received extensive coverage in reviews [255–257], where many studies report 
an improvement in muscle mass, reduction in FM and improved skeletal muscle force and 
power in older healthy men [251,258–261], obese men [262], and in both young and older 
women [263,264]. However, some studies in older men report no change in contractile per-
formance following testosterone provision in men with low baseline testosterone [265–267]. 
In the treatment of obesity, many studies focus on targeting men with high FM and low 
testosterone levels [268]. However, the impact of testosterone administration on muscle 
mass, muscle contractile function and weight status in old obese adults with low muscle 
mass and testosterone levels have received little attention. This may be of particular impor-
tance given that high visceral adiposity may cause itself reduced testosterone levels [269], 
thus potentially accelerating the negative cycle of obesity [238]. 
These pharmacological treatments hold promise for disrupting the negative cycle of 
obesity by improving body composition via an increase in lean tissue mass and reduction 
in FM, though the effect on improving contractile function is more equivocal. Future work 
should aim to identify viable strategies resulting in a safe, but favourable change in all 
three parameters. Figure 3 provides a summary of the discussed strategies to improve 
muscle contractile function and weight status in old-obese populations, with focus on the 
strengths and weaknesses of each strategy. 
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Figure 3. Summary of the strategies used to improve muscle contractile function and body composition in old obese 
populations. Strategies with the weakest or lowest amount of evidence are in the red segments at the bottom of the pyramid, 
whilst strategies with the strongest, most abundant evidence are in the green segments at the top of the pyramid. The key 
strengths and weaknesses attributed to each strategy are listed. Resistance training (RT) and dietary intervention (protein; 
vitamin D) provide clear benefts for favourable changes in muscle mass (MM), muscle contractile function, body mass 
(BM), and overall improved performance and completion of activities of daily living (ADL’s). By contrast, pharmacological 
interventions (resveratrol, hormone replacement therapy [HRT] via testosterone, myostatin inhibition) demonstrate more 
equivocal benefts in old obese populations. Arrows indicate the direction of change in a particular variable: ↑, increase; ↓, 
decrease; ↔, no change. 
10. Conclusions 
The effects of increasing age on skeletal muscle function are well established and there 
is growing evidence to indicate that obesity (or HFD consumption), independent of ageing, 
results in detrimental effects on skeletal muscle function. Whilst there is a strong theoretical 
base that the combined effects of ageing and obesity will accelerate the age-related decline 
in muscle function, the evidence is controversial, which can largely be accounted for by 
methodological discrepancies between published works. Despite the ambiguity, some 
tentative conclusions can be made. Namely, an obesity-induced increase in the maximal 
force and power-producing capacity of postural muscles may be less apparent in old obese 
individuals compared to younger counterparts. Ageing in combination with obesity may 
aggravate the age-related reduction in force to body mass and muscle quality. Such effects 
may have profound consequences for the safe completion of activities of daily living and 
the maintenance of a physically active lifestyle. As such, an obesity-induced exacerbated 
loss in the muscle function of older adults may act as a catalyst for associated negative 
health outcomes in this population. Further work is needed to better understand the 
consequences for muscle function, with a particular focus on injury recovery and periods 
of catabolic crisis. Although dietary interventions to mitigate detrimental effects on muscle 
function should be approached with caution, there is support for the effcacy of resistance 
training. Given the poor adherence to exercise programs, this review explored alternative 
therapeutic strategies for intervention, demonstrating promise for dietary supplementation 
of vitamin D, resveratrol and protein. Where the need to mitigate these effects might be 
more urgent, pharmacological strategies may be effective and present an important area 
for future investigation. 
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